Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable
and clear relationships exist between exposure and treatment outcomes, fixed dosing is still …

… Therapeutic drug monitoring can be a practical tool for personalizing therapy with kinase
inhibitors. The potential of therapeutic drug monitoring for kinase inhibitors is mostly based on …

… There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM)
in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between …

… kinase inhibitors (TKIs) have been developed to block intracellular signaling pathways in
tumor cells. These oral drugs are candidates for therapeutic drug monitoring (… monitoring has …

… kinase domain, which includes binding sites for small molecule tyrosine kinase inhibitors (…
5-thiazolecarboxamide], is a multiple kinase inhibitor that potently inhibits bcr-abl, the sarcoma …

… protein kinases. The overexpression or mutations of genes for these protein kinases may …
development of rationally designed targeted drugs, namely, protein kinase inhibitors (PKIs). …

… kinase inhibitor (KI) in 2001 represented a major shift in the treatment of advanced cancer
away from systemically cytotoxic drugs. In … drug monitoring of small-molecule kinase inhibitors …

Over the past two decades, protein/kinase inhibitors, as targeted therapies, raised in number
and have become increasingly mainstream in the treatment of malignant diseases, thanks …

… Therapeutic drug monitoring (TDM) is a biological monitoring … We report here the use of
therapeutic drug monitoring to … simultaneously by three tyrosine kinase inhibitors for two different …

In recent years new targeted small molecule kinase inhibitors have become available for
pediatric patients with cancer. Relationships between drug exposure and treatment response …